Evotec

Diego Chavez is the CEO of Evotec.

The decision makers in Evotec are Charlie Maher, Christophe Boldron, Dimitar Hristozov, etc. Click to Find Evotec decision makers emails.

Evotec specializes in several therapeutic areas, including oncology, inflammation, infection, pain, neurosciences, central nervous system (CNS) disorders, metabolic diseases, and respiratory diseases. This diverse focus allows Evotec to address a wide range of health challenges and develop innovative solutions tailored to specific patient needs.

Evotec's multimodality platform integrates various scientific disciplines and technologies to streamline the drug development process. By leveraging data-driven research and development (R&D), the platform facilitates the identification of potential drug candidates, optimizes their efficacy and safety profiles, and accelerates the journey from discovery to clinical trials. This comprehensive approach enhances collaboration and efficiency, ultimately leading to more effective therapeutics for patients.

Evotec provides a wide range of services to support drug discovery, including hit identification, lead optimization, preclinical development, and IND (Investigational New Drug) enabling studies. The company also offers expertise in chemistry, biology, and pharmacology, as well as access to advanced technologies and platforms that enhance the drug discovery process. This holistic approach ensures that clients receive tailored support throughout the entire drug development lifecycle.

Yes, Evotec has extensive capabilities in the development of biologics, including monoclonal antibodies, proteins, and gene therapies. The company employs state-of-the-art technologies and methodologies to optimize the design, production, and characterization of biologics, ensuring that they meet regulatory standards and therapeutic efficacy requirements. Evotec's expertise in biologics complements its work in small molecules, providing a comprehensive solution for clients in the biopharmaceutical industry.

Evotec collaborates with a variety of industries, including pharmaceutical, biotechnology, and academic institutions. The company's partnerships span across the entire drug development ecosystem, enabling it to work with clients ranging from small biotech startups to large pharmaceutical companies. This collaborative approach fosters innovation and accelerates the development of new therapeutics, ultimately benefiting patients in need.

Evotec adheres to strict quality assurance and regulatory compliance standards throughout its drug development processes. The company implements robust quality management systems and follows Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) guidelines. Regular audits and continuous training ensure that all staff are up-to-date with industry regulations and best practices, thereby maintaining the highest standards of quality and safety in all projects.